menu
    • menu
    [{"orgOrder":0,"company":"Stalicla","sponsor":"SPRIM Global investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ SPRIM Global investments","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ SPRIM Global investments"},{"orgOrder":0,"company":"Stalicla","sponsor":"Firefly Neuroscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ Firefly Neuroscience","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Firefly Neuroscience"},{"orgOrder":0,"company":"Stalicla","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"mGluR5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Stalicla","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mavoglurant","moa":"mGluR5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"mGluR5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Stalicla

    Menu

    Stalicla

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mavoglurant

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    STALICLA Starts Phase 3 DDI Study of STP7 to Treat Cocaine Use Disorder in the U.S.

    Details : STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM). It is being evaluated for the treatment of cocaine use disorder.

    Product Name : STP7

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 05, 2024

    Lead Product(s) : Mavoglurant

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Study Phase : Phase I

    Sponsor : SPRIM Global investments

    Deal Size : $17.4 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Stalicla Secures $17.4 Million Series B Financing for Precision Neuro Advancements

    Details : Proceeds will support Stalicla's phase 2 Autism Spectrum Disorder (ASD) trial for STP1, a fixed-dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide).

    Product Name : STP1

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 16, 2024

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Sponsor : SPRIM Global investments

    Deal Size : $17.4 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mavoglurant

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase II

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : $270.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Stalicla Signs Exclusive In-Licensing Agreement for Late-Stage Clinical Neuropsychiatric and Neurodevelopmenta...

    Details : Under the terms of the agreement, STALICLA has acquired worldwide rights to AFQ056 (mavoglurant) for substance-use disorders, neurodevelopmental disorders, and other indications. Mavoglurant is a selective non allosteric metabotropic glutamate receptor 5...

    Product Name : STP7

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    September 01, 2023

    Lead Product(s) : Mavoglurant

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase II

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : $270.0 million

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mavoglurant

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase II

    Sponsor : National Institute on Drug Abuse

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Stalicla Signs Cooperative Research And Development Agreement (CRADA) With Us National Institute On Drug Abuse...

    Details : The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.

    Product Name : STP7

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 03, 2023

    Lead Product(s) : Mavoglurant

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase II

    Sponsor : National Institute on Drug Abuse

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Study Phase : Phase I

    Sponsor : Firefly Neuroscience

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    STALICLA and Firefly Neuroscience Enter Partnership Agreement for the Development of Electroencephalogram (EEG...

    Details : STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candi...

    Product Name : STP1

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    March 27, 2023

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Sponsor : Firefly Neuroscience

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder

    Details : In addition to showing good safety and tolerability profile, and dose-dependent target engagement, STP1 treatment resulted in positive signals in clinical markers of neurological and behavioral function, including improved processing speed and crystalliz...

    Product Name : STP1

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    March 24, 2022

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed

    Stalicla

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    STALICLA Translates its Novel Precision Medicine Approach into Clinical Development with First Patient in Phas...

    Details : STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.

    Product Name : STP1

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 12, 2020

    Lead Product(s) : Ibudilast,Bumetanide

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth